GlassScriptPhysician profile
Michael A Albrecht
NPI 1083970172
$3,150.34
in general payments reported to CMS, 2019-2025
30 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,029 · 2020: $78.99 · 2021: $240 · 2022: $556 · 2023: $98.15 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $603.20 | 2019-2025 | Wegovy |
| Sunovion Pharmaceuticals INC. | $429.49 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $279.78 | 2019-2022 | |
| Pfizer INC. | $245.17 | 2019-2022 | |
| Astellas Pharma US INC | $222.66 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $182.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.87 | 2019-2022 | |
| Lilly USA, LLC | $142.69 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Amgen INC. | $121.62 | 2019-2021 | |
| Mylan Specialty L.P. | $91.50 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $61.42 | 2019-2023 | Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $57.75 | 2019-2021 | |
| Dexcom, INC. | $52.53 | 2022 | |
| Daiichi Sankyo INC. | $50.69 | 2019-2022 | |
| Glaxosmithkline, LLC. | $48.11 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $44.75 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $41.70 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $39.15 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.91 | 2022 | |
| Sanofi Pasteur INC. | $34.10 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $34.01 | 2021 | |
| Allergan, INC. | $28.56 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $25.81 | 2025 | Imcivree |
| Takeda Pharmaceuticals U.S.A., INC. | $25.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.28 | 2019-2022 | |
| Genentech USA, INC. | $16.25 | 2020 | |
| Boston Scientific Corporation | $14.31 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.20 | 2022 | |
| Neurelis, INC. | $13.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Albrecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.